Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
RNAi Therapeutics Gaining Ground
Delivery and Specificity Offerings Are Increasing Potential of Young Field
- Inappropriate gene activity is being linked to a growing number of diseases. The ability to modulate or silence such activity via RNA interference (RNAi) technologies could revolutionize the way we treat disease. RNAi, as a new class of drugs, has already been convincingly demonstrated in a number of preclinical ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.